Promoters of IOL Chemicals and Pharmaceuticals Limited confirmed that no encumbrance was created on shares held by the promoter or promoter group during the financial year ended March 31, 2026. This disclosure, submitted to the National Stock Exchange of India Ltd and BSE Limited, ensures compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The declaration provides transparency regarding the holding status of key stakeholders in the company.

The filing was made by Varinder Gupta, a promoter of IOL Chemicals & Pharmaceuticals , on behalf of the listed entities. The confirmation covers both direct and indirect holdings, affirming that the shares remain free from any charges or liabilities for the specified period. This regulatory filing is a standard requirement to update the exchanges on the financial standing of promoter holdings.

The declaration encompasses a list of specific entities and individuals falling under the promoter and promoter group categories. The list includes individuals and corporate entities associated with the company's primary stakeholders.

The submission was addressed to the exchanges and the company's Audit Committee based in Ludhiana. By confirming the absence of encumbrances, the promoters have signaled a stable ownership structure without leveraging shares for financial obligations during FY26.

IOL Chemicals & Pharmaceuticals reported its highest-ever quarterly revenue in Q4FY26, driven by cost optimisation and improved capacity utilisation. Revenue from operations stood at INR619 crore, a 17.4% increase from INR528 crore in the corresponding quarter of the previous year. Profit after tax (PAT) for the quarter surged 68% to INR53 crore, compared to INR32 crore in Q4FY25. The company's EBITDA for the quarter grew by 40% to INR94 crore, with margins expanding by 251 basis points to 15.2%.

Financial Performance

For the full financial year 2026, revenue from operations reached INR2,319 crore, representing an 11.5% year-on-year growth. Full-year EBITDA increased by 29% to INR290 crore, improving the margin to 12.4% from 10.7% in the previous year. PAT for FY26 rose by 36% to INR138 crore. The company incurred capital expenditure of INR160 crore during the year, funded entirely through internal accruals.

Operational Highlights

The pharmaceutical segment saw healthy traction in non-Ibuprofen APIs such as Paracetamol, Metformin, Clopidogrel, and Pantoprazole. The company launched Minoxidil and expanded Pantoprazole capacity during the year. The chemical business also delivered strong performance, with products like ethyl acetate and acetic anhydride running at near-full capacity utilisation of 98% to 100%. The recently commissioned Triacetin plant is expected to further strengthen integration and supply chain efficiencies.

Future Guidance

Looking ahead to FY27, the company expects mid to high-teens revenue growth and aims to achieve EBITDA margins in the range of 14% to 14.5%. Management indicated that capacity utilisation for Paracetamol is expected to rise to 75% in FY27. The company is also progressing with a greenfield project on 100 acres of land near Bathinda, with a total investment outlay estimated between INR1,200 crore and INR1,400 crore over the next four to five years.